In vitro study on anti-inflammatory effects of epigallocatechin-3-gallate-loaded nano- and microscale particles

Yan Ru Wu¹,*, Hong Jin Choi¹,*, Yun Gyeong Kang², Jeong Koo Kim¹,2, Jung-Woog Shin¹,3

¹Department of Health Science and Technology, Inje University, Gimhae, Gyeongnam, Republic of Korea; ²Department of Biomedical Engineering, Inje University, Gimhae, Gyeongnam, Republic of Korea; ³Cardiovascular and Metabolic Disease Center, Institute of Aged Life Redesign, UHARC, Inje University, Gimhae, Gyeongnam, Republic of Korea

*These authors contributed equally to this work

Purpose: This study aimed to develop an anti-inflammation system consisting of epigallocatechin-3-gallate (EGCG) encapsulated in poly(lactide-co-glycolic acid) (PLGA) particles to promote wound healing.

Methods: Nano- and microscale PLGA particles were fabricated using a water/oil/water emulsion solvent evaporation method. The optimal particle size was determined based on drug delivery efficiency and biocompatibility. The particles were loaded with EGCG. The anti-inflammatory effects of the particles were evaluated in an in vitro cell-based inflammation model.

Results: Nano- and microscale PLGA particles were produced. The microscale particles showed better biocompatibility than the nanoscale particles. In addition, the microscale particles released ~60% of the loaded drug, while the nanoscale particles released ~50%, within 48 hours. Thus, microscale particles were selected as the carriers. The optimal EGCG working concentration was determined based on the effects on cell viability and inflammation. A high EGCG dose (100 μM) resulted in poor cell viability; therefore, a lower dose (≤50 μM) was used. Moreover, 50 μM EGCG had a greater anti-inflammatory effect than 10 μM concentration on lipopolysaccharide-induced inflammation. Therefore, 50 μM EGCG was selected as the working dose. EGCG-loaded microparticles inhibited inflammation in human dermal fibroblasts. Interestingly, the inhibitory effects persisted after replacement of the drug-loaded particle suspension solution with fresh medium.

Conclusion: The EGCG-loaded microscale particles are biocompatible and exert a sustained anti-inflammatory effect.

Keywords: wound healing, anti-inflammation, EGCG, microparticles, carriers

Introduction

Nonhealing wounds, including acute wounds and chronic wounds, affect millions of patients in the US annually and are associated with health care costs of over US$25 billion.¹ Impaired wound healing is generally caused by pathological inflammation due to infection or endotoxin. Without effective decontamination, the presence of bacteria and/or endotoxin increases the expression of proinflammatory factors, such as tumor necrosis factor alpha (TNF-α), interleukin (IL) 1β, and IL-6, and prolongs inflammation, which leads to abnormal healing.² Therefore, anti-inflammation systems can be used for the early treatment of wounds.

Epigallocatechin-3-gallate (EGCG), an antioxidant and anti-inflammatory reagent, is the major polyphenol component of green tea. EGCG inhibits inflammation mediated by various cell types, such as immune cells, vascular endothelial cells, and fibroblasts.³–⁵ In addition, it was reported that H-bonding between EGCG and polymers helps EGCG to...
be bonded to polymers. Fibroblasts are the predominant cell type in mammalian skin. Furthermore, EGCG significantly improves initial epithelial neoformation, angiogenesis, and wound contraction; thus, it shows promise for enhancing wound healing. However, the effectiveness of EGCG is dose dependent, and most studies recommend a dose of <100 μM. The optimal dose of EGCG according to indication must be determined.

Controlled drug delivery/release systems, which consist of a drug and its carrier, are currently used to treat wounds. Various biocompatible, biodegradable polymers in the form of nano- or microscale particles are used as carriers in such systems. The size of the particles is related to their toxicity in a manner dependent on the cell type in question.

In this study, we developed an EGCG-loaded particle system for the treatment of inflammation in wound healing. EGCG was encapsulated inside the particles, and this encapsulation prevents its oxidation and maintains its bioactivity. Encapsulation also controls the rate of continuous drug release. This system has promise as a functional dressing for the treatment of nonhealing wounds.

**Materials and methods**

**Fabrication and visualization of particles**

Poly(lactic-co-glycolic acid) (PLGA; 50:50, relative molecular weight =24,000–38,000; Sigma-Aldrich Co., St Louis, MO, USA) particles were prepared by a water/oil/water emulsion solvent evaporation method. Briefly, 10 mg PLGA was dissolved in 1 mL dichloromethane (Junsei Chemical, Tokyo, Chuo-ku, Japan), and 1 mg EGCG (Sigma-Aldrich Co.) in 1 mL distilled water was added to this solution to generate EGCG-loaded particles. Next, 0.7 wt% of the surfactant solvent polyvinyl alcohol (relative molecular weight =13,000–23,000; Sigma-Aldrich Co.) was added. The solution was irradiated for 5 minutes with an ultrasound homogenizer or stirred for 24 hours using a magnetic stir bar to generate nano- or microscale particles, respectively. Particles were then rinsed several times in distilled water, lyophilized for 48 hours, and stored at -70°C. EGCG is known to be sensitive to temperature and light. Therefore, EGCG has been always protected from light during storage and loading into particles. Also, EGCG was kept in a bottle wrapped with aluminum foil at 4°C or lower.

The fabricated PLGA particles were visualized using a field emission scanning electron microscope (SEM; Hitachi Ltd., Tokyo, Japan). The particle size distribution was evaluated by dynamic light scattering (Malvern Instruments, Malvern, UK).

**Cell preparation**

Human dermal fibroblasts (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s Modified Eagle’s Medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 1% penicillin/streptomycin (GE Healthcare Life Sciences, Logan, UT, USA) and 10% fetal bovine serum (Thermo Fisher Scientific). The cells were incubated at 37°C with 5% CO₂ in an incubator until further use.

**Experimental conditions**

**Determination of the particle size**

To determine the proper particle size, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Hoffman-La Roche Ltd., Basel, Switzerland) assays and EGCG release tests were performed. For MTT assay, cells were seeded in 96-well plates at 1×10⁴/cm². After 24 hours, two types of particles (nano- or microscale) at 10, 25, 50, 100, and 200 μg/mL concentrations were added to the cultured cells and incubated for 24 hours. MTT labeling reagent was then added to the cells, followed by incubation for 4 hours at 37°C in 5% CO₂. Solubilization solution was added to the cells for 12 hours to dissolve the crystals. The optical density at 595 nm was measured in each well using a microplate spectrophotometer.

For the selection of particle size, drug-release tests were performed. EGCG-loaded particles (2 mg) were dispersed in 10 mL phosphate-buffered saline and incubated at 37°C with shaking. The absorbance of a mixture (1.0 mL) of the supernatant and acetonitrile/water (70:30, v/v) was determined after 4, 8, 12, 24, and 48 hours using a UV-vis spectrometer. EGCG levels were determined based on the maximum absorption peak at 285 nm and absorption wavelength at 248–328 nm. The efficiency of release was expressed as the percentage of EGCG released compared with the amount loaded.

**Determination of the optimal EGCG concentration**

To evaluate the cytotoxicity induced by EGCG, fibroblasts were seeded in 96-well plates at 1×10⁴/cm². After 24 hours, EGCG (0, 10, 25, 50, or 100 μM) was added to the cells and incubated for 24 hours. Cell viability was evaluated by MTT assay based on the optical density at 595 nm. Anti-inflammatory activity was evaluated in vitro in a cell-based model of inflammation using 100 ng/mL lipopolysaccharide (LPS; Sigma-Aldrich Co.). After treatment with EGCG (0, 10, or 50 μM) for 24 hours, cells were pelleted by centrifugation. Total mRNA was extracted from the cell
Table 1  Inflammatory gene primers used for RT-PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Accession number</th>
<th>Primer sequence</th>
</tr>
</thead>
</table>
| TNF-α    | NM_000594.3      | Forward 5’TCTTCTGAGACACCCTCAACGC3’<br>Reverse 5’AGGCCAAGTTGGAATTCTT3’<br>IL-1β | NM_000576.2 | Forward 5’ACAGGGTGCTCTGGAGATTCT3’<br>Reverse 5’TGAAGGCTTTGCTGATGTT3’<br>IL-6    | NM_000600.4 | Forward 5’CCAGTACCCCCAGAGAAAGA3’<br>Reverse 5’TTGTTTCTGCGAGTCGCTC3’<br>

Abbreviations: TNF-α, tumor necrosis factor-alpha; IL-1β, interleukin-1beta; IL-6, interleukin-6; RT-PCR, reverse transcription polymerase chain reaction.

Results

Visualization of the fabricated particles

SEM images of the fabricated nano- and microscale particles are shown in Figure 1A (×5,000) and B (×1,000). Most of the nanoscale particles were less than 1 μm in diameter (Figure 1C), while the microscale particles ranged from 1 to 20 μm in diameter (Figure 1D).

Efficacy of the microscale particles as drug carriers: biocompatibility and drug release

The results of MTT assays of cells exposed to the particles without EGCG are shown in Figure 2A and B. Almost more than half of the cells were damaged by the nanoscale particles, irrespective of the concentration. However, most cells survived treatment with the microscale particles, irrespective of the concentration. There was no concentration equivalent to IC50 in the range of application when microscale particles were used. But when nanoscale particles were introduced, IC50 can be estimated as ~50 μg/mL.

EGCG release from the nanoscale and microscale particles is shown in Figure 2C and D. Almost 60% of the EGCG was released from the microscale particles by 12 hours; no additional release was observed thereafter. In contrast, <40% of the EGCG was released from the nanoscale particles in 12 hours.

EGCG exerts dose-dependent cytotoxic and anti-inflammatory effects

The effect of EGCG (0–100 μM) on fibroblasts was evaluated by MTT assay at 24 and 72 hours (Figure 3A; n=6). Cell proliferation tended to decrease with increasing EGCG concentration, and this effect was enhanced after 72 hours. These results suggest that high doses of EGCG inhibit fibroblast growth; therefore, ≤50 μM doses of EGCG were evaluated. The effects of ≤50 μM EGCG on inflammation in fibroblasts after 24 hours were verified by RT-PCR (Figure 3B; n=3). A greater anti-inflammatory effect was exerted by 50 μM than by 10 μM EGCG. Based on these results, microscale particles were loaded with 50 μM EGCG for subsequent experiments.

Statistical analysis

Differences were subjected to one-way analysis of variance using SPSS version 19.0K software (SPSS Inc., Chicago, IL, USA). A value of P<0.05 was considered to indicate statistical significance.
and again at 8 hours after replacing the microscale particle-loaded medium with fresh medium. The expression of TNF-α and IL-6, but not IL-1β, was significantly decreased at 24 hours after administration of the EGCG-loaded microparticles (Figure 4A). TNF-α, IL-1β, and IL-6 expression was significantly decreased at 8 hours after medium replacement (Figure 4B). Therefore, the EGCG-loaded microparticles exerted a sustained anti-inflammatory effect.

**Discussion**

The aim of this study was to develop an anti-inflammation system to suppress the inflammation associated with wounding. The proposed system consists of EGCG encapsulated in biodegradable/nontoxic PLGA particles, which continuously release EGCG.

The effect of particle size on drug delivery and/or release has been investigated extensively. Particles <10 μm in diameter are phagocytized by immune cells, leading to the loss of the encapsulated drug. In contrast, particles >200 μm in diameter induce immune and inflammatory reactions. In addition, drug delivery/release efficiency is influenced by particle size, shape, stiffness, and degradation rate. Spherical particles have the greatest diameter-to-surface area ratio. We did not assess the effect of stiffness, as the particles used in this study will be applied to the skin. Drug release assays were conducted up to 48 hours to mimic real-world conditions, ie, changing of wound dressings at <24-hour intervals. The microscale particles released more than half of the encapsulated EGCG within 12 hours, with no significant release thereafter. This suggests that a significant proportion of the EGCG was released within 12 hours.
of the PLGA particles were degraded within 8 hours. When PLGA is prepared in the form of volumetric structure or mixed with other materials, it usually needs 8 weeks or more to be degraded.20,21 In other previous studies, 50%–80% of the encapsulated drug was released within less than 12 hours upon bursting of the PLGA particles.22,23 In this study, the amount of released EGCG was calculated and expressed as a percentage of the amount added during the initial particle preparation. This percentage is expected to be high if based on the actual amount of the EGCG encapsulated. However, the purpose of this experiment was to identify the drug release pattern in terms of the timing of the drug release.

Figure 2 Effects of EGCG on cell viability and the pattern of drug release. Relative optical density values of the (A) nanoscale and (B) microscale particles. Drug release from (C) nanoscale and (D) microscale particles (n=3); *P<0.05.

Abbreviation: EGCG, epigallocatechin-3-gallate.

---

Figure 3 Effects of various concentrations of EGCG on (A) cell viability of intact fibroblasts (n=6) and (B) anti-inflammation in LPS-induced inflammatory fibroblasts as determined by RT-PCR (n=3); *P<0.05.

Abbreviations: EGCG, epigallocatechin-3-gallate; IL-1β, interleukin-1 beta; IL-6, interleukin-6; LPS, lipopolysaccharide; OD, optical density; RT-PCR, reverse transcription polymerase chain reaction; TNF-α, tumor necrosis factor-alpha.
and the point at which it was no longer released. Therefore, a sufficient quantity of EGCG was considered to be released from the loaded microscale particles within 12 hours, as most wound dressings are recommended to be replaced within less than 24 hours.

EGCG has potential for treatment of a broad range of diseases, such as diabetes, hypertension, and neurological diseases, based on its anti-inflammatory and antioxidant effects. However, our results (Figure 3A) suggested that EGCG has poor bioavailability when applied at high concentrations. An EGCG concentration >100 μM reportedly causes oxidative DNA damage and increases H2O2 production, while >200 μM EGCG affects cell-cycle progression. Therefore, the applied dose of EGCG should be carefully controlled. In this study, 50 μM EGCG was used to treat inflammation; this is a safe concentration based on the viability test. The EGCG-loaded microparticles suppressed the expression of TNF-α, IL-1β, and IL-6 at 24 hours (Figure 4A). Moreover, TNF-α, IL-1β, and IL-6 expression was significantly reduced at 8 hours after medium replacement (Figure 4B).

This study had several limitations. We did not investigate the effects of our system on wound healing processes such as migration, neoformation, or angiogenesis. However, a previous animal study demonstrated that EGCG improved epithelial neoformation, from 27.32% (vehicle control) to 48.20% (EGCG). Furthermore, enhancements of angiogenesis and granulation tissue formation in vivo by EGCG have been reported. To our knowledge, no study has evaluated the effects of EGCG-loaded PLGA particles on healing. Therefore, further research in animal models is warranted.

In conclusion, EGCG-loaded microscale particles inhibited inflammation, and this effect was sustained even after removal of the drug.

**Acknowledgment**

This work was supported by the Human Resource Training Program for Regional Innovation and Creativity through the Ministry of Education and National Research Foundation of Korea (NRF-2014H1C1A1073148).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

Anti-inflammatory effects of EGCG-loaded nano- and microscale particles